Enovis (NYSE:ENOV) Updates FY 2026 Earnings Guidance

Enovis (NYSE:ENOV) issued an update on its FY 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 3.520-3.730 for the period, compared to the consensus earnings per share estimate of 3.540. The company issued revenue guidance of $2.3 billion-$2.4 billion, compared to the consensus revenue estimate of $2.3 billion.

Analyst Ratings Changes

ENOV has been the topic of several recent analyst reports. Wall Street Zen cut Enovis from a “buy” rating to a “hold” rating in a research report on Saturday. Zacks Research upgraded Enovis from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 29th. Wells Fargo & Company cut their price objective on Enovis from $40.00 to $39.00 and set an “overweight” rating for the company in a research report on Friday. BTIG Research raised their target price on Enovis from $39.00 to $40.00 and gave the company a “buy” rating in a report on Thursday. Finally, BMO Capital Markets restated an “outperform” rating and set a $30.00 target price on shares of Enovis in a research report on Friday. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $42.00.

Enovis Price Performance

Shares of NYSE:ENOV traded up $0.38 during trading on Friday, hitting $26.68. 2,058,436 shares of the stock were exchanged, compared to its average volume of 1,111,529. The company has a fifty day moving average price of $24.62 and a two-hundred day moving average price of $23.97. The company has a market cap of $1.54 billion, a PE ratio of -1.39 and a beta of 1.34. The company has a current ratio of 1.98, a quick ratio of 1.05 and a debt-to-equity ratio of 0.84. Enovis has a 12-month low of $19.14 and a 12-month high of $34.28.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.05. The firm had revenue of $582.78 million during the quarter, compared to the consensus estimate of $581.84 million. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.Enovis’s quarterly revenue was up 3.2% on a year-over-year basis. During the same period last year, the business posted $0.79 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, analysts forecast that Enovis will post 3.12 EPS for the current year.

Insider Activity

In other Enovis news, insider Oliver Engert acquired 1,200 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were acquired at an average cost of $21.62 per share, for a total transaction of $25,944.00. Following the transaction, the insider directly owned 51,840 shares of the company’s stock, valued at approximately $1,120,780.80. This represents a 2.37% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Over the last three months, insiders acquired 4,200 shares of company stock worth $92,084. Insiders own 2.90% of the company’s stock.

More Enovis News

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Enovis reported second-quarter adjusted earnings of $0.90 per share, above the $0.85 analyst consensus and up from $0.79 a year earlier. Revenue of $582.8 million was also slightly ahead of estimates, while sales increased 3.2% year over year. Enovis Q2 Earnings and Revenue Estimates
• Positive Sentiment: Management reaffirmed its full-year 2026 outlook, including revenue of approximately $2.3 billion to $2.4 billion and adjusted EPS guidance of $3.52 to $3.73. Reconstructive sales were a relative bright spot, rising 8% on a reported basis and 6% organically. Enovis Announces Second Quarter 2026 Results
• Positive Sentiment: BTIG Research raised its price target from $39 to $40 and maintained a Buy rating, implying substantial potential upside from recent trading levels. BTIG Research Price Target
• Neutral Sentiment: Wells Fargo lowered its price target modestly from $40 to $39 but retained an Overweight rating, indicating continued long-term confidence despite near-term concerns. Wells Fargo Price Target
• Negative Sentiment: The market reaction was negative because Enovis’ second-quarter performance was characterized as “softer than expected.” Although revenue and EPS exceeded published estimates, investors appear focused on the relatively modest 3% reported sales growth and the lack of an upward guidance revision. Enovis Shares Drop After Second-Quarter Earnings
• Negative Sentiment: Enovis continues to report a deeply negative GAAP net margin, which may reinforce investor concerns about profitability and execution even though adjusted earnings improved. Enovis Q2 2026 Earnings Call Transcript

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Corient Private Wealth LLC raised its holdings in shares of Enovis by 540.7% in the fourth quarter. Corient Private Wealth LLC now owns 55,180 shares of the company’s stock worth $1,470,000 after acquiring an additional 46,568 shares during the last quarter. Front Street Capital Management Inc. boosted its stake in shares of Enovis by 75.8% during the fourth quarter. Front Street Capital Management Inc. now owns 361,932 shares of the company’s stock valued at $9,642,000 after acquiring an additional 156,069 shares during the last quarter. XTX Topco Ltd purchased a new stake in Enovis during the 4th quarter worth about $561,000. Susquehanna Portfolio Strategies LLC raised its stake in Enovis by 249.9% in the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 140,997 shares of the company’s stock valued at $3,756,000 after purchasing an additional 100,704 shares during the last quarter. Finally, Twinbeech Capital LP acquired a new position in Enovis in the 4th quarter valued at about $1,998,000. 98.45% of the stock is currently owned by institutional investors and hedge funds.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.